CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 13.47: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.98%Above 5Y avg (1.89%)
Annual Rate
CNY 0.52Paid semi-annual
Payout Ratio
40.9%Sustainable
Payback Period
50.5 yr
Last Ex-Dividend
Jun 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.28BCNY785.93M · vs all stocks (USD)
Trailing P/E
21.51xRevenue (TTM)
990.68MCNY147.32M · vs all stocks (USD)
Profit Margin
25.65%Beta
0.2770xvs all stocks
52-Week Change
-27.90%vs all stocks
Forward Annual Dividend Yield
1.98%vs all stocks
Market Capitalization
5.28BCNY785.93M · vs all stocks (USD)
Enterprise Value
4.51BCNY671.13M · vs all stocks (USD)
Trailing P/E
21.51xPrice to Sales (TTM)
5.55xPrice to Book (MRQ)
2.20xEnterprise to Revenue
4.55xEnterprise to EBITDA
17.20xGross Margin
90.15%Profit Margin
25.65%Operating Margin
22.48%Return on Assets (TTM)
5.76%Return on Equity (TTM)
10.51%Revenue (TTM)
990.68MCNY147.32M · vs all stocks (USD)
Revenue per Share (TTM)
4.95CNYUpdated Aug 21, 2026Quarterly Revenue Growth
12.20%Gross Profit (TTM)
887.60MCNY131.99M · vs all stocks (USD)
EBITDA (TTM)
293.22MCNY43.60M · vs all stocks (USD)
Net Income (TTM)
254.07MCNY37.78M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-15.20%Operating Cash Flow (TTM)
182.34MCNY27.12M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.29MCNY-3.17M · vs all stocks (USD)
Forward Annual Dividend Rate
0.5200CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
1.98%vs all stocks
Trailing Annual Dividend Rate
0.5200CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.98%vs all stocks
5-Year Average Dividend Yield
1.89%vs all stocks
Payout Ratio
40.94%Minority Interest (Equity)
19.60MCNYFY2025 · Dec 31, 2025Revenue
966.07MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
101.82MCNYFY2025 · Dec 31, 2025Gross Profit
864.25MCNYFY2025 · Dec 31, 2025Operating Income
248.70MCNY36.98M · vs all stocks (USD)
Pre-tax Income
301.13MCNYFY2025 · Dec 31, 2025Income Tax Expense
40.14MCNYFY2025 · Dec 31, 2025Net Income
261.00MCNYFY2025 · Dec 31, 2025EBIT
301.40MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
316.55MCNYFY2025 · Dec 31, 2025Research & Development
40.70MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
373.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
16.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.76MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
267.02KCNYFY2025 · Dec 31, 2025EPS (Basic)
1.31CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.31CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
199.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
199.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
261.00MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
609.11KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
197.73MCNYFY2025 · Dec 31, 2025Free Cash Flow
83.14MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
780.73MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
261.00MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-377.81KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-61.00MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.89MCNYFY2025 · Dec 31, 2025Capital Expenditures
-114.59MCNYFY2025 · Dec 31, 2025Net Acquisitions
-20.38MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.00MCNYFY2025 · Dec 31, 2025Sale of Investments
2.97MCNYFY2025 · Dec 31, 2025Other Investing Activity
-132.57MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-274.57MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-103.70MCNYFY2025 · Dec 31, 2025Other Financing Charges
63.85MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-39.86MCNYFY2025 · Dec 31, 2025Shares Outstanding
199.43MSharesUpdated Aug 21, 2026Float Shares
61.16MSharesUpdated Aug 21, 2026% Held by Insiders
70.70%vs all stocks
% Held by Institutions
2.65%vs all stocks
Total Cash (MRQ)
770.25MCNY114.54M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.86CNYUpdated Aug 21, 2026Total Debt (MRQ)
1.68MCNY250.48K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0007xCurrent Ratio (MRQ)
9.35xBook Value per Share (MRQ)
12.44CNYUpdated Aug 21, 2026Total Assets
2.72BCNY404.06M · vs all stocks (USD)
Total Current Assets
1.25BCNYFY2025 · Dec 31, 2025Total Liabilities
267.47MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.46BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
90.45MCNYFY2025 · Dec 31, 2025Total Current Liabilities
177.01MCNYFY2025 · Dec 31, 2025Cash
780.73MCNYFY2025 · Dec 31, 2025Cash Equivalents
590.00KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
781.32MCNYFY2025 · Dec 31, 2025Other Short-term Investments
37.03MCNYFY2025 · Dec 31, 2025Accounts Receivable
224.17MCNYFY2025 · Dec 31, 2025Inventory
34.07MCNYFY2025 · Dec 31, 2025Accounts Payable
74.29MCNYFY2025 · Dec 31, 2025Short-term Debt
16.52MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.91MCNYFY2025 · Dec 31, 2025Long-term Debt
2.20MCNYFY2025 · Dec 31, 2025Common Stock (Book)
199.43MCNYFY2025 · Dec 31, 2025Retained Earnings
807.96MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.45BCNY364.29M · vs all stocks (USD)
52-Week Low
22.82CNYUpdated Aug 21, 202652-Week High
44.68CNYUpdated Aug 21, 202652-Week Change
-27.90%vs all stocks
Beta
0.2770xvs all stocks
50-Day MA
25.23CNYUpdated Aug 21, 2026200-Day MA
28.05CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.85MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.52MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.27CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 13.47: safe zoneNotable
Altman Z-Score: 13.47
High structural barrier to entryNotable
Barrier to Entry: 0.51
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Pharma Research Products Co., Ltd
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Krafton Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth